|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SBNO1 |
Gene summary for SBNO1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SBNO1 | Gene ID | 55206 |
| Gene name | strawberry notch homolog 1 | |
| Gene Alias | MOP3 | |
| Cytomap | 12q24.31 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A3KN83 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55206 | SBNO1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.62e-04 | -2.86e-01 | 0.0155 |
| 55206 | SBNO1 | HTA11_347_2000001011 | Human | Colorectum | AD | 4.48e-04 | 4.05e-01 | -0.1954 |
| 55206 | SBNO1 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 2.40e-04 | 9.91e-01 | 0.3487 |
| 55206 | SBNO1 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.36e-05 | 6.22e-01 | 0.281 |
| 55206 | SBNO1 | A001-C-207 | Human | Colorectum | FAP | 4.28e-02 | -1.85e-01 | 0.1278 |
| 55206 | SBNO1 | A015-C-203 | Human | Colorectum | FAP | 9.90e-12 | -2.19e-01 | -0.1294 |
| 55206 | SBNO1 | A015-C-204 | Human | Colorectum | FAP | 2.72e-03 | -1.36e-01 | -0.0228 |
| 55206 | SBNO1 | A002-C-201 | Human | Colorectum | FAP | 1.87e-07 | -1.22e-01 | 0.0324 |
| 55206 | SBNO1 | A001-C-108 | Human | Colorectum | FAP | 1.02e-04 | 3.08e-02 | -0.0272 |
| 55206 | SBNO1 | A002-C-205 | Human | Colorectum | FAP | 2.53e-10 | -2.13e-02 | -0.1236 |
| 55206 | SBNO1 | A015-C-006 | Human | Colorectum | FAP | 2.88e-08 | 5.28e-02 | -0.0994 |
| 55206 | SBNO1 | A015-C-106 | Human | Colorectum | FAP | 1.16e-02 | -2.05e-03 | -0.0511 |
| 55206 | SBNO1 | A002-C-114 | Human | Colorectum | FAP | 4.09e-11 | -2.65e-01 | -0.1561 |
| 55206 | SBNO1 | A015-C-104 | Human | Colorectum | FAP | 3.94e-12 | -1.13e-01 | -0.1899 |
| 55206 | SBNO1 | A001-C-014 | Human | Colorectum | FAP | 1.35e-04 | -8.35e-02 | 0.0135 |
| 55206 | SBNO1 | A002-C-016 | Human | Colorectum | FAP | 7.38e-10 | -1.58e-01 | 0.0521 |
| 55206 | SBNO1 | A015-C-002 | Human | Colorectum | FAP | 2.19e-06 | -2.01e-01 | -0.0763 |
| 55206 | SBNO1 | A002-C-116 | Human | Colorectum | FAP | 1.09e-15 | -1.20e-01 | -0.0452 |
| 55206 | SBNO1 | A014-C-008 | Human | Colorectum | FAP | 9.28e-06 | -1.01e-01 | -0.191 |
| 55206 | SBNO1 | A018-E-020 | Human | Colorectum | FAP | 1.79e-11 | -2.14e-01 | -0.2034 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SBNO1 | SNV | Missense_Mutation | c.3455N>C | p.Gly1152Ala | p.G1152A | A3KN83 | protein_coding | tolerated(0.17) | benign(0.057) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | SD | ||
| SBNO1 | SNV | Missense_Mutation | c.1601N>A | p.Arg534Gln | p.R534Q | A3KN83 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A0A9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
| SBNO1 | SNV | Missense_Mutation | c.2533N>G | p.Gln845Glu | p.Q845E | A3KN83 | protein_coding | tolerated(0.62) | benign(0.025) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SBNO1 | SNV | Missense_Mutation | c.2288N>A | p.Pro763Gln | p.P763Q | A3KN83 | protein_coding | deleterious(0.03) | probably_damaging(0.982) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SBNO1 | SNV | Missense_Mutation | novel | c.868N>G | p.Leu290Val | p.L290V | A3KN83 | protein_coding | deleterious(0) | possibly_damaging(0.888) | TCGA-BH-A1F2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| SBNO1 | SNV | Missense_Mutation | c.637N>G | p.Phe213Val | p.F213V | A3KN83 | protein_coding | tolerated(0.08) | benign(0.13) | TCGA-BH-A1FC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SBNO1 | SNV | Missense_Mutation | c.1000N>C | p.Ile334Leu | p.I334L | A3KN83 | protein_coding | tolerated(0.24) | benign(0.074) | TCGA-D8-A1JG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| SBNO1 | SNV | Missense_Mutation | c.3212N>A | p.Phe1071Tyr | p.F1071Y | A3KN83 | protein_coding | deleterious(0) | probably_damaging(0.926) | TCGA-D8-A1Y0-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cyclophosphamide+methotrexatum+fluorouracillum | SD | |
| SBNO1 | SNV | Missense_Mutation | novel | c.868N>G | p.Leu290Val | p.L290V | A3KN83 | protein_coding | deleterious(0) | possibly_damaging(0.888) | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD |
| SBNO1 | SNV | Missense_Mutation | novel | c.2935G>A | p.Gly979Arg | p.G979R | A3KN83 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-OL-A66J-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |